Bayer Articles

CELLTECH REDUCES LOSSES IN 1st HALF

31 May 1993

BRAZILIAN DRUG PROFITS TO BE INVESTIGATED

24 May 1993

CELLTECH PRODUCT PIPELINE UPDATE

24 May 1993

TOKYO STOCK COMMENT

24 May 1993

SCIOS NOVA HAS THREE DRUGS IN CLINICAL TRIALS

17 May 1993

CELLTECH'S ANTI-TNF: PHASE I STUDY

10 May 1993

T-PA BACKED BY GUSTO STUDY RESULTS

10 May 1993

SPANISH FIRM ESTEVE INTERNATIONALIZES

10 May 1993

BAYER'S 1st QTR PROFIT SLUMPS

10 May 1993

PORTUGAL'S OTC DRUG MARKET GROWING FAST

3 May 1993

DRUG FIRMS TO WORK TOGETHER ON AIDS R&D

26 April 1993

EISAI AND BAYER COLLABORATION

26 April 1993

BAYER PHARMA APPOINTMENT

19 April 1993

GERMAN PATENT COVER "THREAT"

19 April 1993

BAYER INVESTMENT IN ASIA

12 April 1993

MERCK AG BACKS SELF-MEDICATION IN EUROPE

12 April 1993

EUROPE STOCK COMMENT

5 April 1993

SWEDEN'S PHARMA MARKET IN 1992

5 April 1993

BAYER ITALY HIT BY EXCHANGE RATES

5 April 1993

MERCK & CO "MOST ADMIRED" US FIRM

29 March 1993

PROFITS DOWN AT BAYER

22 March 1993

MILES HEALTHCARE NEW PRESIDENT

22 March 1993

MILES' KOGENATE APPROVED IN USA

15 March 1993

PHARMACEUTICAL DESIGN: EPITOPE SELECTION

15 March 1993

SCIOS NOVA HAS BROAD TECHNOLOGY BASE

8 March 1993

BRAZIL GOVT BANS 34 "INEFFECTIVE" DRUGS

8 March 1993

BAYER NIMODIPINE TRIAL

1 March 1993

SIGNIFICANT MOVES BY PHARMA COS IN FT 500

1 March 1993

PFIZER DISREGARDS WSJ "SCARE STORY"

15 February 1993

CELLTECH GROUP POSTS 1992 RESULTS

8 February 1993

2.7% GROWTH FOR EUROPEAN ANALGESICS

18 January 1993

DEUTSCHE BANK BUY/SELL RECCOMENDATIONS

4 January 1993

UK INDUSTRY PROTEST OVER NHS LIST PLANS

4 January 1993

GLOBAL DRUG MARKET: 30 YEARS OF GROWTH

4 January 1993

US OTC ANALGESICS - A 1992 RETROSPECTIVE

4 January 1993

SWITCHING POM TO OTC IN THE UK

14 December 1992

ICI AT "BREAKING POINT" WITH DEMERGER

14 December 1992

EURO HEALTH CARE STOCK PERFORMANCE

7 December 1992

BAYER ESPANA LICENSING DEAL

7 December 1992

MEXICO "WILL BE COMPETITIVE UNDER NAFTA"

9 November 1992

EUROPE STOCK COMMENT

9 November 1992

LOWER PROFITS FORCAST FROM BAYER

9 November 1992

SUCCESSFUL POM-TO-P SWITCHES IN THE UK

9 November 1992

EUROPE STOCK COMMENT

2 November 1992

CHEMICAL INSIGHT INDUSTRIAL RANKINGS

5 October 1992

EUROPE STOCK COMMENT

5 October 1992

ICI AND MILES TO COPROMOTE CIPRO

5 October 1992

EUROPE STOCK COMMENT

7 September 1992

EUROPE STOCK COMMENT

3 August 1992

JAPAN'S NEW PHARMA TARIFF

3 August 1992

Study on ciprofloxacin interactions

29 June 1992

BAYER LAUNCHES OTC IMIDAZOLE IN UK

1 June 1992

STERLING WINTHROP/BAYER LAWSUIT RESULT

25 May 1992

CELLTECH AND BAYER IN SEPSIS DEAL

25 May 1992

BAYER ESPANA'S 1991 PROFITS DOWN 21.4%

25 May 1992

WORLD BRIEFS

18 May 1992

JAPAN SUBSIDS DO WELL FOR MNCs

18 May 1992

APPOINTMENTS AT BAYER

4 May 1992

STOCK MARKET COMMENTARY: EUROPE

4 May 1992

BAYER'S CIPROXIN & UTIs

27 April 1992

TWO NEW LICENSING DEALS FOR ROBERTS

20 April 1992

BAYER JAPAN PROFITS BOOST

13 April 1992

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

EURO DRUGMAKERS STOCK "UNDERVALUED"

6 April 1992

ASPIRIN HELPS BAYER IN ITALY

6 April 1992

MILES STAFF CUTS

6 April 1992

BAYER DIAGNOSTICS' NEW INSTRUMENT

6 April 1992

MILES STAFF CUTS

6 April 1992

BAYER DIAGNOSTICS' NEW INSTRUMENT

6 April 1992

ASPIRIN HELPS BAYER IN ITALY

6 April 1992

EURO DRUGMAKERS STOCK "UNDERVALUED"

6 April 1992

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

SELF-MEDICATION IN EUROPE IN THE 1990s

23 March 1992

FROM A RESEARCH-LED TO A MARKET-DRIVEN FIRM

23 March 1992

FROM A RESEARCH-LED TO A MARKET-DRIVEN FIRM

23 March 1992

GERMANY'S HOECHST, BAYER PROFITS DOWN

16 March 1992

STOCK MARKET COMMENTARY: EUROPE

16 March 1992

NORTH AMERICA'S OTC COUGH COLD MARKET

9 March 1992

BAYER AG'S JONATHAN TALBUTT

9 March 1992

STOCK MARKET COMMENTARY: EUROPE

10 February 1992

ALZHEIMER'S DISEASE: A GROWING BURDEN

20 January 1992

ALZA PRODUCT PROMOTIONS

20 January 1992

ANALGESICS IN THE USA -- AN OPEN DOOR FOR P&G?

6 January 1992

Bayer Austria chief appointed to Pharmig board